These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Karpf AR. Epigenetics; 2006 Jul; 1(3):116-20. PubMed ID: 17786175 [Abstract] [Full Text] [Related]
7. Infrequent and low expression of cancer-testis antigens located on the X chromosome in colorectal cancer: implications for immunotherapy in South African populations. Dakshinamurthy AG, Ramesar R, Goldberg P, Blackburn JM. Biotechnol J; 2008 Nov; 3(11):1417-23. PubMed ID: 18956367 [Abstract] [Full Text] [Related]
8. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, Goulmy E. Blood; 2009 Mar 19; 113(12):2715-22. PubMed ID: 19096014 [Abstract] [Full Text] [Related]
9. Immunological and functional aspects of MAGEA3 cancer/testis antigen. Das B, Senapati S. Adv Protein Chem Struct Biol; 2021 Mar 19; 125():121-147. PubMed ID: 33931137 [Abstract] [Full Text] [Related]
13. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. James SR, Link PA, Karpf AR. Oncogene; 2006 Nov 02; 25(52):6975-85. PubMed ID: 16715135 [Abstract] [Full Text] [Related]
14. Epigenetic targets for immune intervention in human malignancies. Maio M, Coral S, Fratta E, Altomonte M, Sigalotti L. Oncogene; 2003 Sep 29; 22(42):6484-8. PubMed ID: 14528272 [Abstract] [Full Text] [Related]